Top AI drug discovery companies in 2026 include Recursion Pharmaceuticals, Insilico Medicine, Atomwise, Nimbus Therapeutics, BenevolentAI, XtalPi, and others leveraging machine learning, generative AI, and computational chemistry for oncology, rare diseases, and more.1
NVIDIA and Eli Lilly announced a $1 billion, five-year co-innovation AI lab in San Francisco using BioNeMo platform and 'scientist in the loop' framework to accelerate drug discovery with continuous learning between wet and dry labs.27
2026 marks AI becoming core to drug discovery, with in silico target identification, digital twins in clinical development, and integrated computational approaches reducing late-stage failures.3
Pharma giants like Eli Lilly, GSK, and Pfizer launched AI platform deals with startups such as Chai Discovery, Noetik, and Boltz for biologics design, cancer prediction, and small molecule discovery.4
North American firms lead with high-throughput data and partnerships, while Asia's XtalPi and Deep Intelligent Pharma advance physics-based AI and automation.1
Sources:
1. https://www.pharmanow.live/ai-in-pharma/top-ai-drug-discovery-companies-2026
2. https://healthtechmagazine.net/article/2026/01/nvidia-and-lilly-announce-co-innovation-ai-lab-accelerate-drug-discovery
3. https://www.drugtargetreview.com/article/192243/2026-the-year-ai-stops-being-optional-in-drug-discovery/
4. https://www.genengnews.com/topics/artificial-intelligence/pharma-bets-big-on-ai-platforms-with-flurry-of-new-year-deals/